ReviewArchives of microbiology2024
Azole resistance in Aspergillus fumigatus- comprehensive review.
Review in Archives of microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Functional characterization of SHC-like triterpene cyclase genes in azole response and virulence-related traits ofVirulence · 2026Article
- Therapeutic Failure in Invasive Fungal Infections: Beyond Antifungal Resistance-A Narrative Review.Journal of fungi (Basel, Switzerland) · 2026Review
- Diagnostic Failure in Invasive Fungal Infections: Causes, Clinical Consequences, and Mitigation Strategies.Journal of fungi (Basel, Switzerland) · 2026Review
- Molecular and Phenotypic Characterization of Multidrug-ResistantJournal of fungi (Basel, Switzerland) · 2026Article
- Pulmonary Aspergillosis in an Infant with Multiple Hepatic Hemangiomas.Children (Basel, Switzerland) · 2026Article
- Directed evolution of the pathogenic moldAntimicrobial agents and chemotherapy · 2026Article
- Azole Antifungals Under Pressure: Therapeutic Challenges and Multifaceted Resistance Mechanisms.Current medicinal chemistry · 2026Review
- Detection of TR34/L98H pan-azole-resistantFrontiers in fungal biology · 2026Article
- Current Evidence on Voriconazole Exposure and Individualized Therapy for Aspergillosis.Infection and drug resistance · 2026Review
- Pathogenesis and Triazole Resistance inInfection and drug resistance · 2026Review
- Research progress on the current status of respiratory pathogen infections and their detection methods.Frontiers in microbiology · 2026Review
- A quiet but growing threat: Global perspectives on antifungal resistance and future therapeutic approaches.Indian journal of pharmacology · 2026Review
- Sargassum incisifolium and Ulva spp metabolites activity and their molecular dynamics simulation against Fusarium oxysporum 14-alpha-demethylase.Biotechnology reports (Amsterdam, Netherlands) · 2025Article
- Contribution of the CYP51A Y119F Mutation to Azole Resistance inJournal of fungi (Basel, Switzerland) · 2025Article
- Does the use of topical azoles have an impact on antifungal resistance?The Journal of antimicrobial chemotherapy · 2025Article
- Article
- Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives.Infectious disease reports · 2025Review
- Adaptation Under Pressure: Resistance and Stress Response Interplay in ClinicalJournal of fungi (Basel, Switzerland) · 2025Article
- Doubling of triazole resistance rates in invasive aspergillosis over a 10-year period, Belgium, 1 April 2022 to 31 March 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Epidemiological characteristics of patients with invasive pulmonary aspergillosis infected with Aspergillus fumigatus from a tertiary hospital in Ningxia, China.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspergillus fumigatus is a ubiquitous filamentous fungus commonly found in the environment. It is also an opportunistic human pathogen known to cause a range of respiratory infections, such as invasive aspergillosis, particularly in immunocompromised individuals. Azole antifungal agents are widely used for the treatment and prophylaxis of Aspergillus infections due to their efficacy and tolerability. However, the emergence of azole resistance in A. fumigatus has become a major concern in recent years due to their association with increased treatment failures and mortality rates. The development of azole resistance in A. fumigatus can occur through both acquired and intrinsic mechanisms. Acquired resistance typically arises from mutations in the target enzyme, lanosterol 14-α-demethylase (Cyp51A), reduces the affinity of azole antifungal agents for the enzyme, rendering them less effective, while intrinsic resistance refers to a natural resistance of certain A. fumigatus isolates to azole antifungals due to inherent genetic characteristics. The current review aims to provide a comprehensive overview of azole antifungal resistance in A. fumigatus, discusses underlying resistance mechanisms, including alterations in the target enzyme, Cyp51A, and the involvement of efflux pumps in drug efflux. Impact of azole fungicide uses in the environment and the spread of resistant strains is also explored.
Indexed as
Identifiers
38878211What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.